. Priority of invention depends on the date on which the invention was conceived, the date on which it was actually or constructively reduced to practice, and the diligence of a party who was first to conceive but last to reduce to practice. See 35 U.S.C.A. § 102(g) (West 1984 This article provides a historical perspective for the patenting of gene sequences and describes the fundamentals and evolution of patent law. It summarizes federal technology transfer law and policy and assesses the impacts of patenting on academic research. The patentability of gene sequences is then considered along with potential impacts that published sequence data may have on obtaining patent protection for downstream products. Industry's position on gene patenting is summarized and perspectives from the emerging public record on these issues are presented. The article discussing points at which the filing of patent applications and the licensing of patents may be appropriate. It concludes that technology transfer policies for genome research must be adopted carefully so that they remain viable in a time of rapid technological change.
The public benefits from its support of biomedical research through advances at the frontiers of knowledge as well as through the development of commercial health care products (1) . While the internationalization of scientific research and the pursuit of patent protection are not incompatible (2) , the question of when to The Just as nonscientists involved in science policy must understand the differences between, for example, structure-and function-based research, and the importance of both approaches, scientists involved in technology transfer policy must understand patent law and product development. Other areas of research involving unprecedented amounts of data about informational molecules, such as structure-based (or "rational") drug design, raise similar patent and technology transfer questions. It would be unfortunate if misconceptions about the patent system lead to a self-fulfilling prophesy that international research cooperation will be impaired.
"Gene Patenting" Issues in Perspective
Genes traditionally were identified and cloned through a functional approach, starting with samples having observed biological activities, working backward to isolate and purify the responsible proteins, and then, through the use of degenerate DNA probes, locating the corresponding gene. Once a programmatic decision was made to characterize the human genome through a large-scale structural (in other words, sequence-based) approach, the present debate became inevitable. Wide dissemination of sequence data will encourage research, but due consideration must be given to protecting the market exclusivity necessary for the private sector to risk enormous sums of money in product development efforts. The biotechnology industry is critically dependent upon patent protection to maintain its threatened leadership in highly competitive world markets. How to apply patent rights to genome research should have been a widely debated question, but it largely went unresolved during the establishment of the human genome project. Although the Office of Technology Assessment (OTA) concluded in 1988 that "genome projects raise no new questions of patent or copyright law," it did not consider how technology transfer principles would apply to sequence data that identified genes (6) . Contemporaneously, the National Research Council rhetorically considered whether a central agency of the government should own the patents for commercially valuable new DNA clones, but concluded only that genome sequences should not be copyrighted (7) . Contributing to this lack of foresight may have been an urgency to start the genome program, the absence of any expectation that gene sequences would be identifiable so soon with so little accompanying functional information, a general unfamiliarity with patent law (8) , and a historical lag in the ..
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Historical perspective is important to the consideration of gene-related patents (10) . For example, when the landmark "Cohen and Boyer" patent for recombinant DNA issued in 1980 (11) , critics asserted that a preoccupation with patenting would destroy the academic tradition of freely exchanging and publishing information. It was contended that the best minds were being diverted into development at the expense of solving more basic biological research problems. These fears proved to be unwarranted, and several observers correctly had predicted "that just as branches of chemistry and physics evolved an acceptable association with industry, so will molecular biology, without rending itself apart" (12) . The biotechnology industry presently sponsors academic research, conducts elegant independent studies, relieves academia of repetitive and technical tasks, provides employment opportunities for postdoctoral scientists, and offers the promise of revolutionizing medicine and agriculture.
Fundamentals of Patent Law
A patentable discovery or invention must be useful, novel, and nonobvious (13 Decisions about patentability, infringement, and the proper scope of protection (as defined by the claims to be accorded to inventions in biotechnology) will be based on older court decisions that have been developed for technological advances in organic and pharmaceutical chemistry. For example, the burgeoning chemical industry after World War II flooded the PTO with patent applications, yet basic legal questions of prima facie obviousness (is a new structural formula that resembles a known compound unpatentable) were not answered until the 1960s, and basic questions of enablement (the amount of "teaching" required in a patent application) were not answered until the 1970s. This body of law is relevant but is not necessarily a close fit to advances in biotechnology, and answers to the same patent law questions vary internationally (18) .
Living microorganisms were determined in 1980 to be patentable subject matter by a 5 to 4 Supreme Court majority (19). Transgenic plants and animals subsequently were determined to be patentable by the PTO, although human beings are not patentable because the U.S. Constitution forbids the ownership of people. Linear informational molecules such as proteins and DNA sequences have been patented for many years without a perceived need for guidance by the courts.
Other concerns have also been expressed. A few commentators have suggested that the patenting of partial or full gene sequences is unethical on the theory that this would limit public access to our universal heritage (20) . Similar criticism was offered against the patenting of microorga-nisms, plants, and animals. There is validity to concerns that developing countries, for many reasons unrelated to patenting, do not fully participate in biotechnological advances. These issues are not unique to genome research and warrant due consideration.
Hybridomas as an example of transition in patent law. are not mandatory for the development of all gene-related or other products, whether inventions are "patentable may determine whether research efforts are accelerated by the hope of reward or slowed by want of incentives" (19).
Companies are unlikely to invest significant research efforts or to develop commercial DNA-based products that might infringe another's patent rights without first obtaining permission in advance through a license. If the applicant for a patent decides to permit an allowed patent to issue, its claims may be dedicated to the public or licensed. The ways that patented inventions are licensed to transfer technology (that is, exclusively, nonexclusively, or perhaps through a lottery) may be as important to encouraging product development as when a specific invention (such as cDNA or genomic DNA sequences) is patentable. The licensing of government-developed inventions by law is announced publicly, and terms and conditions, such as royalty rates, are negotiated (32). Questions about the impacts of patenting and licensing on academic research, however, are critical considerations in establishing a policy for the transfer of technology resulting from the genome research.
Effects of Patenting on Academic Research
Concerns about a negative impact of patenting DNA sequences on the conduct of genome research are largely theoretical. A frequently misunderstood concept about patenting is that liability for infringement attaches only to commercial activities rather than to academic studies as a practical matter. Virtually all of the relevant court cases involve disputes between commercial competitors over manufacturing-related activities or product sales (33) , and purely academic research appears not to have been enjoined (34 Are such DNA sequences paentably novel and nonobvious? "Taken together, the novelty and nonobviousness requirements express a congressional determination that the purposes behind the [Patent Law] are best served by free competition and exploitation of that which is either already available to the public, or that which may be readily discerned from publicly available material" (43). Novelty means that an invention did not previously exist in the public domain. NIH sought patent protection contemporaneously with the publication of the cDNA sequences because absolute novelty is a requirement for patentability in most countries, even though the United States provides a 1-year grace period. A nonobvious invention is an invention that could not have been made with a reasonable expectation of success by a hypothetical person of "ordinary skill" in the relevant scientific field from publicly available information and material.
The NIH cDNA patent application claims "enriched" or "purified" full-length polynucleotide sequences, which are related to genes that do not exist naturally in these forms. Uniqueness in the context of GenBank, other sequence databases, and published articles assures with a reasonable certainty that such sequences are novel (44) , although once again the PTO will have to decide.
As noted above in the case of hybridomas, rapid scientific advances first expand and then somewhat contract the boundaries of patentable subject matter as revelatory laboratory techniques quickly become technologically and legally mundane. For example, the creation of recombinant DNA in 1972, for which Paul Berg received a Nobel Prize in 1980, may now be accomplished in some circumstances by workers of ordinary skill with a reasonable expectation of success (45) . Patents are generally no longer allowed merely for the recombinant expression of a known protein, and patent legislation has been proposed to make such products patentable as an incentive for their commercial development (46) .
As a matter of logic, one could not reasonably have expected to make any particular purified cDNA or genomic gene sequence corresponding to a previously unknown human gene even for use as a probe (47) . One would have expected to find some important gene sequences in a cDNA library, but "obvious to try" is not the applicable legal standard (48). The manner in which an invention actually was made, however, whether through serendipity or a rapid computer-assisted analysis, does not negate nonobviousness (49). Nonobviousness will require another PTO decision. Patenting is not a value judgment about the elegance of an invention's underlying discovery, and the standards for patentability differ from the criteria applied to publication in peer-reviewed journals.
How broadly can gene sequence discoveries be patented? An inventor may claim everything that can be done with an invention described in a patent application to the extent that a worker skilled in the relevant field is "enabled" by the patent to make and use that invention without "undue experimentation" (50) . If expensive. For example, as discussed above, the production of monoclonal antibodies against a known antigen or the expression of recombinant proteins from an identified gene sequence generally is not considered to require undue experimentation.
Several cases are relevant to the issue of enablement. For example, the PTO ruled in 1987 that it would have been obvious (that is, readily discernable from publicly available material) to prepare a genomic library from bovine placenta in 1982 and to isolate by hybridization the gene encoding bovine growth hormone (51) . A patent also was issued in 1987 claiming a general method of identifying genes for known proteins by preparing and probing an appropriate cDNA library and then isolating the responsible cDNA (52) . The issuance of the patent implies that successfully utilizing this technique to produce intact cDNA coding sequences would not require undue experimentation.
The relative ease or difficulty of obtaining complete sequences for individual genes from a partial cDNA or genomic DNA sequence and the relevant cDNA or genomic DNA libraries may vary. When fulllength coding sequences can be obtained through even a dozen or more conventional sequencing steps without undue experimentation, a patent application disclosing partial gene sequences should entitle their discoverers to patent the full cDNA coding sequence. The fact that the set of sequences may contain a few that cannot be applied to the asserted use does not negate the patentability of the rest (53).
In a case now pending on appeal, Biogen, Inc., contends that a skilled worker in 1980 would have been able to isolate and sequence the gene for interferon without undue experimentation by stimulating cellular production of that protein, isolating cellular messenger RNA, preparing a cDNA library, screening the library for a cDNA that would cause a transfected cell to exhibit antiviral activity, and sequencing and expressing the interferon cDNA (54 General effects of publication on downstream patenting. The patent system encourages the filing of patent applications as early as possible, in part to permit publication without jeopardizing potential patent rights. Whether or not sequences of unknown function are patentable, the effect of publication of sequence data on the patentability of downstream discoveries is still unknown (58) . To some extent, the impact of FfO determinations of novelty and nonobviousness will depend upon what becomes readily discernable beyond the sequences actually published (59) , and on the technical feasibility of extending partial sequences to full length and of expressing the full-length coding regions. As sequencing technology advances, there will come a time-if it is not yet here-when there may be little difference in effect between the publication of partial and full coding sequences. It will take the PTO and the courts several years, however, before they will construe the 1992 level of technological skill.
Also relevant to assessing the impact of 912 publication will be the impetus for further investigation of particular sequences. About one-fifth of the partial cDNA sequences in the NIH patent application appear to correspond to specific genes previously identified in other species, and it has been estimated that as many as onethird of full cDNA coding sequences for expressed genes will at least have a recognizable general function (60) . For these subsets of gene sequences, a relatively stronger motivation exists for expressing them and developing monoclonal antibodies against their expression products. Conventional technology and commercial services exist to accomplish both steps.
Would sufficient development incentives remain? If partial or full cDNA sequences without apparent biological function enter the public domain through publication, the sequences themselves would remain unpatentable even if applications were discovered later to genetic therapy or other emerging DNA-based therapies such as triple helix DNA or antisense RNA. Once their biological function is determined, pharmaceutical "compositions of matter" incorporating the cDNA expression products may still be patentable (61 Interpreting the Public Record Industry, academia, and NIH share the view that patenting and licensing should be pursued at the stage of research at which they will encourage commercial product development. The concerns of the academic community about the impacts of patents on genome research may be unfounded, but must be acknowledged. In assessing the recommendations of industry, it is clear that the trade associations are not interested in exclusively licensing sequences of unknown function, assuming that they are patentable, as an incentive for product development. It remains to be determined whether the nonexclusive licensing of such sequences would protect U.S. industrial interests, because U.S. law favors domestic manufacture of products sold in the United States (66), or facilitate achieving international agreement. However, when to file patent applications and when (and how) to license them are separate questions that may warrant different answers.
Even if the publication of partial sequences without known function rendered the full gene sequence unpatentable, industry has not expressed concerns that there would be insufficient remaining patent protection for expression products to encourage product development. Once even a general function seems apparent, however, publication alone would appear more seriously to threaten patenting for future products; if so, patenting and licensing by NIH at this stage may well serve the public interest. Until this point is clarified by PTO decisions or specifically addressed by industry, perhaps patenting and licensing optimally should be pursued only for complete coding portions of a gene for which a generalized biological function seems apparent, or at least for partial genes of sufficient lengths to surmise their function (5) .
Given the uncertainty about the impact of publishing partial sequences on patenting full-length sequences, it may be prudent to file patent applications claiming sequences of unproven function-but not to permit them to issue as patents or, alternatively, not to license them. This would preserve early filing dates to support NIH's own future continuation-in-part patent applications once sequences were fully characterized. Again, the decision of when to file patent applications depends on future PTO decisions about gene sequences.
Achieving international agreement on an appropriate policy may be surprisingly quick, given the public positions taken by the French emerge, the relevance of patent law to biotechnology must be evaluated carefully. Perhaps amending the obviousness requirement of the patent law would be salutary. Additionally, strengthening use patents internationally may become necessary to ensure adequate protection for sequence-related inventions in world markets. In the software field, the appropriateness and effectiveness of patent or copyright protection has been identified as warranting reassessment (67) . Perhaps patenting is not the optimal system when unprecedented volumes of data about informational molecules are published. A registration system, like copyright, might be simpler and more affordable. To encourage the development of other important technologies, federal laws were enacted to create new intellectual property systems that would protect novel plant varieties and semiconductor chip masks (68, 69) . This approach might be necessary for DNA sequence inventions.
Conclusions
The President's Council on Competitiveness has noted that for biotechnology "the appropriate definition of intellectual property rights is a crucial area requiring careful thought" (70) . Creating appropriate definitions and developing responsible policies to attain the goals of advancing knowledge and developing products will require the concerted efforts of government, academia, and industry. Given the rapid pace of technological development, we must anticipate where research is heading to ensure that the policies we make today are valid even a year from now. Understanding the systems of both science and patent law are necessary for success in this endeavor.
